Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Fresenius Medical Care AG & Co KGaA ST buy Riccardo

Start price
€44.91
08.02.11 / 50%
Target price
€49.00
16.02.11
Performance (%)
6.46%
End price
€47.81
16.02.11
Summary
This prediction ended on 16.02.11 with a price of €47.81. With a performance of 6.46%, the BUY prediction by Riccardo for Fresenius Medical Care AG & Co KGaA ST closed with a slight gain. Riccardo has 50% into this prediction

Fresenius Medical Care is a leading global provider of dialysis products, services and care, particularly for patients with chronic kidney disease. It operates in over 120 countries and cares for over 345,000 patients worldwide. The company specializes in renal care, manufacturing and distributing products related to dialysis and providing clinical care as well as education and support services for patients with kidney disease. Fresenius Medical Care has been listed on the Frankfurt Stock Exchange since 1996 and on the New York Stock Exchange since 1997. Its symbol, FMCQF, represents its over-the-counter (OTC) stock symbol in the United States.

Performance without dividends (%)
Name 1w 1m 1y 3y
Fresenius Medical Care AG & Co KGaA ST -2.929% -2.929% -4.981% -41.731%
iShares Core DAX® -0.205% 2.949% 17.330% 18.203%
iShares Nasdaq 100 1.613% 5.877% 37.451% 56.281%
iShares Nikkei 225® -0.740% -1.256% 11.847% 5.531%
iShares S&P 500 0.267% 3.240% 29.308% 46.371%

Comments by Riccardo for this prediction

In the thread Fresenius Medical Care AG & Co KGaA ST diskutieren
Prediction Buy
Perf. (%) 6.46%
Target price 49.000
Change
Ends at 16.02.11

Fresenius Medical Care ist wieder erwacht

Aktionäre von Fresenius Medical Care brauchen einen langen Anlagehorizont. Der Dialysespezialist kauft das Blutwäschegeschäft der Euromedic-Gruppe. Dafür hat Fresenius Medical Care rund eine halbe Milliarde Euro bezahlt. Damit baut man seinen Marktanteil in Rumänien, Russland, Türkei, Polen und auf dem Balkan weiter aus und stärkt die Präsenz. Zudem erhält man Kliniken in Portugal und Griechenland. Analysten rechnen damit, dass sich der Kauf erst im Jahr 2012 beim Gewinn positiv bemerkbar machen wird. Sie müssen wissen, dass IDC Gewinne schreibt und großes Wachstum verspricht. Ich würde langfristig investiert bleiben...

Prediction Buy
Perf. (%) 6.46%
Target price 49.000
Change
Ends at 16.02.11

(Vom Mitglied beendet)